WEKO3
アイテム
{"_buckets": {"deposit": "4a3d3ad7-3d3b-4e15-af4b-f4414774c3e9"}, "_deposit": {"created_by": 2, "id": "5660", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "5660"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00005660", "sets": ["30"]}, "author_link": ["24086", "24082", "24084", "24087", "24089", "24083", "24081", "24078", "24079", "24088", "24085", "24090", "24080"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2014-07-27", "bibliographicIssueDateType": "Issued"}, "bibliographicPageEnd": "1318", "bibliographicPageStart": "1314", "bibliographicVolumeNumber": "20", "bibliographic_titles": [{"bibliographic_title": "Medical Science Monitor"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: High-dose (4.0 g/day) mesalazine is typically used for induction therapy, but its efficacy as maintenance therapy remains to be determined. We conducted a multicenter retrospective study to investigate the efficacy of continuous treatment with 4.0 g/day of mesalazine. Material/Methods: Japanese ulcerative colitis (UC) patients receiving acute induction therapy with 4.0 g/day mesalazine were enrolled and followed. Those who clinically improved or who achieved clinical remission were categorized into 2 sub-groups according to the median duration of treatment with 4.0 g/day of mesalazine. The clinical relapse frequency and the time to relapse were analyzed. Results: We enrolled 180 patients with active UC, and then 115 patients who clinically improved or who achieved clinical remission after treatment with 4.0 g/day mesalazine were categorized into 2 sub-groups according to the median of treatment duration: a short-term treatment group (?105 days, n=58) and a long-term treatment group (\u003e105 days, n=57). Overall, 45 (39.1%) patients relapsed: 28 (48.3%) in the short-term treatment group and 17 (29.8%) in the long-term treatment group. This difference was statistically significant (p\u003c0.05). The relapse- free rate in the long-term treatment group was significantly higher than that in the short-term treatment group (p\u003c0.05). The mean time to relapse in the long-term treatment group was significantly longer than that in the short-term treatment group (425.6±243.8 days vs. 277.4±224.5 days; p\u003c0.05). Conclusions: Long-term continuous treatment with high-dose mesalazine (4.0 g/day) may be more effective than short-term treatment for maintenance of remission in UC patients.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Medical Science Monitor, 20, pp.1314-1318; 2014", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "International Scientific Literature Inc."}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.12659/MSM.890567", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c Med Sci Monit, 2014."}, {"subitem_rights": "This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "16433750", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Takeshima, Fuminao"}], "nameIdentifiers": [{"nameIdentifier": "24078", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsumura, Masato"}], "nameIdentifiers": [{"nameIdentifier": "24079", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Makiyama, Kazuya"}], "nameIdentifiers": [{"nameIdentifier": "24080", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohba, Kazuo"}], "nameIdentifiers": [{"nameIdentifier": "24081", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamakawa, Masaki"}], "nameIdentifiers": [{"nameIdentifier": "24082", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishiyama, Hitoshi"}], "nameIdentifiers": [{"nameIdentifier": "24083", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamao, Takuji"}], "nameIdentifiers": [{"nameIdentifier": "24084", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Akazawa, Yuko"}], "nameIdentifiers": [{"nameIdentifier": "24085", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamaguchi, Naoyuki"}], "nameIdentifiers": [{"nameIdentifier": "24086", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohnita, Ken"}], "nameIdentifiers": [{"nameIdentifier": "24087", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ichikawa, Tatsuki"}], "nameIdentifiers": [{"nameIdentifier": "24088", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Isomoto, Hajime"}], "nameIdentifiers": [{"nameIdentifier": "24089", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakao, Kazuhiko"}], "nameIdentifiers": [{"nameIdentifier": "24090", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "MSM20_1314.pdf", "filesize": [{"value": "180.6 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 180600.0, "url": {"label": "MSM20_1314.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/5660/files/MSM20_1314.pdf"}, "version_id": "726086ae-2db1-4b2c-b22d-27c6caa27d87"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Colitis, ulcerative - prevention \u0026 Control", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Colitis, ulcerative - therapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Mesalamine - administration \u0026 Dosage", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis"}]}, "item_type_id": "2", "owner": "2", "path": ["30"], "permalink_uri": "http://hdl.handle.net/10069/34743", "pubdate": {"attribute_name": "公開日", "attribute_value": "2014-10-03"}, "publish_date": "2014-10-03", "publish_status": "0", "recid": "5660", "relation": {}, "relation_version_is_last": true, "title": ["Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis"], "weko_shared_id": -1}
Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis
http://hdl.handle.net/10069/34743
http://hdl.handle.net/10069/34743c2b24037-15c1-445c-9c69-0afc3b483c58
名前 / ファイル | ライセンス | アクション |
---|---|---|
MSM20_1314.pdf (180.6 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2014-10-03 | |||||
タイトル | ||||||
タイトル | Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Colitis, ulcerative - prevention & Control | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Colitis, ulcerative - therapy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Mesalamine - administration & Dosage | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Takeshima, Fuminao
× Takeshima, Fuminao× Matsumura, Masato× Makiyama, Kazuya× Ohba, Kazuo× Yamakawa, Masaki× Nishiyama, Hitoshi× Yamao, Takuji× Akazawa, Yuko× Yamaguchi, Naoyuki× Ohnita, Ken× Ichikawa, Tatsuki× Isomoto, Hajime× Nakao, Kazuhiko |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background: High-dose (4.0 g/day) mesalazine is typically used for induction therapy, but its efficacy as maintenance therapy remains to be determined. We conducted a multicenter retrospective study to investigate the efficacy of continuous treatment with 4.0 g/day of mesalazine. Material/Methods: Japanese ulcerative colitis (UC) patients receiving acute induction therapy with 4.0 g/day mesalazine were enrolled and followed. Those who clinically improved or who achieved clinical remission were categorized into 2 sub-groups according to the median duration of treatment with 4.0 g/day of mesalazine. The clinical relapse frequency and the time to relapse were analyzed. Results: We enrolled 180 patients with active UC, and then 115 patients who clinically improved or who achieved clinical remission after treatment with 4.0 g/day mesalazine were categorized into 2 sub-groups according to the median of treatment duration: a short-term treatment group (?105 days, n=58) and a long-term treatment group (>105 days, n=57). Overall, 45 (39.1%) patients relapsed: 28 (48.3%) in the short-term treatment group and 17 (29.8%) in the long-term treatment group. This difference was statistically significant (p<0.05). The relapse- free rate in the long-term treatment group was significantly higher than that in the short-term treatment group (p<0.05). The mean time to relapse in the long-term treatment group was significantly longer than that in the short-term treatment group (425.6±243.8 days vs. 277.4±224.5 days; p<0.05). Conclusions: Long-term continuous treatment with high-dose mesalazine (4.0 g/day) may be more effective than short-term treatment for maintenance of remission in UC patients. | |||||
書誌情報 |
Medical Science Monitor 巻 20, p. 1314-1318, 発行日 2014-07-27 |
|||||
出版者 | ||||||
出版者 | International Scientific Literature Inc. | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 16433750 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.12659/MSM.890567 | |||||
権利 | ||||||
権利情報 | c Med Sci Monit, 2014. | |||||
権利 | ||||||
権利情報 | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Medical Science Monitor, 20, pp.1314-1318; 2014 |